Emerald Mutual Fund Advisers Trust Has $3,575,000 Stake in Tabula Rasa Healthcare Inc. (NASDAQ:TRHC)

Emerald Mutual Fund Advisers Trust continued to hold its position in shares of Tabula Rasa Healthcare Inc. (NASDAQ:TRHC) during the second quarter, Holdings Channel reports. The institutional investor owned 237,543 shares of the company’s stock at the end of the second quarter. Emerald Mutual Fund Advisers Trust’s holdings in Tabula Rasa Healthcare were worth $3,575,000 as of its most recent filing with the SEC.

Several other institutional investors have also recently modified their holdings of the stock. TIAA CREF Investment Management LLC boosted its position in shares of Tabula Rasa Healthcare by 108.5% in the first quarter. TIAA CREF Investment Management LLC now owns 8,131 shares of the company’s stock valued at $110,000 after buying an additional 4,232 shares during the period. Bank of New York Mellon Corp purchased a new position in shares of Tabula Rasa Healthcare during the first quarter valued at about $178,000. Russell Investments Group Ltd. boosted its position in shares of Tabula Rasa Healthcare by 58.1% in the second quarter. Russell Investments Group Ltd. now owns 94,089 shares of the company’s stock valued at $1,415,000 after buying an additional 34,565 shares during the period. Hood River Capital Management LLC boosted its position in shares of Tabula Rasa Healthcare by 30.1% in the first quarter. Hood River Capital Management LLC now owns 767,501 shares of the company’s stock valued at $10,346,000 after buying an additional 177,774 shares during the period. Finally, Wellington Management Group LLP boosted its position in shares of Tabula Rasa Healthcare by 37.2% in the first quarter. Wellington Management Group LLP now owns 782,142 shares of the company’s stock valued at $10,544,000 after buying an additional 212,164 shares during the period. Institutional investors own 25.11% of the company’s stock.

Tabula Rasa Healthcare (NASDAQ:TRHC) last posted its quarterly earnings data on Monday, May 1st. The company reported $0.04 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.06 by $0.02. The business had revenue of $27.70 million during the quarter, compared to analysts’ expectations of $26 million. The business’s quarterly revenue was up 37.1% on a year-over-year basis.

Several equities analysts have recently issued reports on the company. UBS AG reiterated a “buy” rating and set a $17.00 price target (down from $18.00) on shares of Tabula Rasa Healthcare in a research report on Thursday, May 25th. Stifel Nicolaus lowered their price target on Tabula Rasa Healthcare from $19.00 to $16.00 and set a “buy” rating on the stock in a research report on Tuesday, May 2nd. Zacks Investment Research upgraded Tabula Rasa Healthcare from a “sell” rating to a “hold” rating in a research report on Thursday, April 13th. Finally, Chardan Capital assumed coverage on Tabula Rasa Healthcare in a research report on Monday, July 10th. They set a “buy” rating and a $19.50 price target on the stock. One research analyst has rated the stock with a hold rating and six have given a buy rating to the company. Tabula Rasa Healthcare presently has a consensus rating of “Buy” and an average target price of $17.25.

In other Tabula Rasa Healthcare news, insider Orsula V. Knowlton sold 8,000 shares of the company’s stock in a transaction on Wednesday, May 17th. The shares were sold at an average price of $11.94, for a total transaction of $95,520.00. Following the completion of the sale, the insider now owns 919,407 shares in the company, valued at approximately $10,977,719.58. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Glen R. Bressner bought 7,500 shares of the company’s stock in a transaction on Thursday, May 18th. The shares were acquired at an average price of $11.96 per share, with a total value of $89,700.00. Following the transaction, the director now directly owns 18,256 shares in the company, valued at approximately $218,341.76. The disclosure for this purchase can be found here. In the last ninety days, insiders have sold 46,759 shares of company stock worth $634,444. Company insiders own 45.80% of the company’s stock.

About Tabula Rasa Healthcare

Tabula Rasa HealthCare, Inc (Tabula Rasa), formerly CareKinesis, Inc, is a provider of patient-specific, data-driven technology and solutions that enable healthcare organizations to optimize medication regimens to improve patient outcomes, reduce hospitalizations and manage risk. The Company delivers its solutions through a suite of technology-enabled products and services for medication risk management, which includes bundled prescription fulfillment and adherence packaging services for client populations with complex prescription needs.

Want to see what other hedge funds are holding TRHC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Tabula Rasa Healthcare Inc. (NASDAQ:TRHC).